Want to see HK:6855 full AI Analyst Report?
Top Page
Ascentage Pharma Group International
(6855)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$36.00
▼(-29.27% Downside)
Action:Reiterated
Date:08/06/26
The score is primarily held back by weak financial performance—deep losses and accelerating cash burn despite strong revenue growth and high gross margins. Technicals add pressure with the stock trading below major moving averages and negative MACD. Valuation is neutral-to-weak because the negative P/E is driven by losses and there is no dividend yield data.
Positive Factors
Strong Revenue Growth
Rapid revenue expansion indicates improving commercial traction and growing demand for the company’s oncology-focused pipeline. If sustained, stronger top-line scale can support future operating leverage as products advance and commercialization capabilities develop.
Negative Factors
Deep and Worsening Losses
Persistent and worsening losses show that revenue growth has not yet translated into an economically sustainable business. Continued high research, development and commercial expenses could delay breakeven and increase the need for additional capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Rapid revenue expansion indicates improving commercial traction and growing demand for the company’s oncology-focused pipeline. If sustained, stronger top-line scale can support future operating leverage as products advance and commercialization capabilities develop.
Read all positive factors
Ascentage Pharma Group International (6855) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$12.68B
Dividend YieldN/A
Average Volume (3M)2.92M
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth70.26%
EPS Growth-12.79%
CountryHK
Employees828
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.89
Shares Outstanding373,616,240
10 Day Avg. Volume3,525,639
30 Day Avg. Volume2,923,719
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)12.61
Price to Sales (P/S)29.89
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$44.36Price Target Upside-12.84% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.92
Revenue Forecast (FY)HK$826.98M
Ascentage Pharma Group International Business Overview & Revenue Model
Company Description
Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations are conce...
How the Company Makes Money
Ascentage Pharma primarily makes money through (1) collaboration and licensing arrangements and (2) potential product commercialization as its drug candidates advance toward approval. Collaboration/licensing revenue can include upfront payments, r...
Ascentage Pharma Group International Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 632.78M | 559.26M | 980.65M | 221.98M | 209.71M | 27.91M |
| Gross Profit | 516.09M | 427.35M | 951.57M | 191.44M | 187.71M | 24.58M |
| EBITDA | -1.30B | -1.10B | -299.63M | -743.61M | -835.99M | -915.99M |
| Net Income | -1.45B | -1.21B | -405.43M | -925.64M | -882.92M | -782.42M |
Balance Sheet | ||||||
| Total Assets | 3.24B | 3.97B | 2.62B | 2.50B | 2.83B | 2.94B |
| Cash, Cash Equivalents and Short-Term Investments | 1.90B | 2.47B | 1.26B | 1.10B | 1.50B | 1.75B |
| Total Debt | 2.09B | 1.98B | 1.67B | 1.80B | 1.79B | 1.08B |
| Total Liabilities | 2.67B | 2.63B | 2.34B | 2.43B | 2.42B | 1.71B |
| Stockholders Equity | 556.29M | 1.33B | 264.19M | 60.42M | 408.66M | 1.23B |
Cash Flow | ||||||
| Free Cash Flow | -1.40B | -1.20B | -135.65M | -782.92M | -857.20M | -1.04B |
| Operating Cash Flow | -1.38B | -1.17B | -111.36M | -726.08M | -653.91M | -604.68M |
| Investing Cash Flow | 613.95M | -1.00B | -362.04M | 21.92M | -384.61M | -466.52M |
| Financing Cash Flow | 1.70B | 2.54B | 314.77M | 368.75M | 619.27M | 1.78B |
Ascentage Pharma Group International Technical Analysis
Negative
50.90
Price Trends
35.15
Negative
37.34
Negative
44.64
Negative
Market Momentum
-0.34
Negative
49.17
Neutral
46.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6855, the sentiment is Negative. The current price of 50.9 is above the 20-day moving average (MA) of 34.40, above the 50-day MA of 35.15, and above the 200-day MA of 44.64, indicating a bearish trend. The MACD of -0.34 indicates Negative momentum. The RSI at 49.17 is Neutral, neither overbought nor oversold. The STOCH value of 46.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6855.
Ascentage Pharma Group International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$22.06B | 23.85 | 12.35% | ― | 117.39% | ― | |
58 Neutral | HK$11.70B | -169.02 | -1.02% | ― | 192.64% | 92.31% | |
52 Neutral | HK$22.71B | -14.63 | -27.40% | ― | 5.38% | 16.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$9.72B | -19.53 | -43.54% | ― | 116.67% | -0.42% | |
45 Neutral | HK$12.68B | -7.52 | -153.78% | ― | 70.26% | -12.79% | |
44 Neutral | HK$7.96B | -71.58 | -9.49% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
HK:6855
Ascentage Pharma Group International
34.18
-44.72
-56.68%
HK:9688
Zai Lab Ltd
20.00
-4.60
-18.70%
HK:9969
InnoCare Pharma Ltd.
14.48
-2.89
-16.64%
HK:1952
Everest Medicines Ltd.
31.22
-28.98
-48.14%
HK:2171
CARsgen Therapeutics Holdings Ltd.
13.43
-7.31
-35.25%
HK:2616
CStone Pharmaceuticals
6.17
-5.64
-47.75%
Ascentage Pharma Group International Corporate Events
Ascentage Pharma Lifts Revenue, Deepens Losses as U.S. Push and BTK Degrader Trials Advance
Aug 19, 2026
Ascentage Pharma reported a 29.3% year-on-year rise in interim revenue to RMB302.2 million for the six months ended June 30, 2026, driven by a 32.6% increase in product sales, notably Lisaftoclax. Operating expenses climbed 36.1% to RMB1,042.7 mil...
Ascentage Pharma Sets Board Meeting to Approve 2026 Interim Results
Aug 5, 2026
Ascentage Pharma Group International has scheduled a board meeting for August 19, 2026, to review and potentially approve the group’s unaudited interim results for the six months ended June 30, 2026, and to authorize their publication. This ...
Ascentage Pharma Strengthens Global Commercial Push With Senior Executive Hires
Aug 2, 2026
Ascentage Pharma has appointed Faiçal Miyara as Chief Business Officer to lead global business development and Jim Ziegler as Chief Commercial Officer to head commercialization of its products in the U.S. and other ex-China markets. Both exec...
Ascentage Pharma Sets Up $200 Million Nasdaq ATM Offering Program
Jul 19, 2026
Ascentage Pharma has filed an automatic shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission, qualifying as a well-known seasoned issuer and enabling future offerings of American depositary shares. The filing i...
Ascentage Pharma Corrects AGM Date for Share Incentive Scheme Mandate
Jul 13, 2026
Ascentage Pharma Group International has clarified an administrative detail related to its employee incentive plans, correcting the date of the annual general meeting at which the scheme mandate limit for the 2021 and 2022 RSU schemes and the post...
Ascentage Pharma Grants New RSUs to 453 Employees Under 2021 Scheme
Jun 29, 2026
Ascentage Pharma Group International has approved a further grant of restricted share units under its 2021 RSU Scheme, issuing 440,743 RSUs to 453 employees of the Group. The awards, which require no purchase price from recipients, will be satisfi...
Ascentage Pharma Showcases Broad Leukemia Data for Olverembatinib and Lisaftoclax at EHA2026
Jun 14, 2026
Ascentage Pharma reported 17 clinical updates at the European Hematology Association Congress, highlighting progress for its key drugs olverembatinib and lisaftoclax in multiple blood cancers. The data underscore the company’s strategy to mo...
Ascentage Pharma Trustee Buys Shares to Fund 2022 RSU Scheme
Jun 11, 2026
Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme has purchased 110,000 existing shares on the open market to satisfy future RSU vesting obligations. The shares, acquired on 11 June 2026...
Ascentage Pharma Trustee Buys Shares to Fund 2022 RSU Incentive Scheme
Jun 10, 2026
Ascentage Pharma Group International has disclosed that the trustee of its 2022 restricted share unit scheme purchased 190,000 existing shares on the market on June 10, 2026, representing about 0.0509% of issued share capital, at an average price ...
Ascentage Pharma Trustee Buys Shares to Fund 2022 RSU Scheme
May 28, 2026
Ascentage Pharma Group International has disclosed that its trustee purchased 50,000 existing shares on the market on May 28, 2026, for about HK$1.91 million to support its 2022 Restricted Share Unit Scheme. These shares, representing roughly 0.01...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.